Stay updated with breaking news from Radcom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee has a lot to discuss Nov. 17, but only one voting question: Does the evidence demonstrate that Merck & Co. Inc.’s gefapixant provides a clinically meaningful benefit to adults with refractory or unexplained chronic cough?
Dime Community Bancshares (NASDAQ:DCOM – Get Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Monday. Separately, Raymond James reduced their price target on Dime Community Bancshares from $27.00 to $23.00 and set an “outperform” rating for the company in a […]
Had it been asked to, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee would have voted Oct. 31 to recommend approval of Vertex Pharmaceutical Inc. and Crispr Therapeutics AG’s exagamglogene autotemcel, or exa-cel, as a one-time transformative treatment for severe sickle cell disease in individuals 12 and older.
StockNews.com began coverage on shares of RADCOM (NASDAQ:RDCM – Free Report) in a report released on Monday. The brokerage issued a buy rating on the technology company’s stock. RADCOM Stock Performance NASDAQ:RDCM opened at $7.99 on Monday. The stock has a 50-day simple moving average of $8.67 and a two-hundred day simple moving average of […]
Brown Advisory Inc. lessened its holdings in shares of Dime Community Bancshares, Inc. (NASDAQ:DCOM – Free Report) by 7.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 692,086 shares of the savings and loans company’s stock after selling 52,635 shares during the period. […]